Syncom Formulations (India) Limited (SYNCOMF.BO)
INR 21.07
(0.0%)
INR 21.07
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 942.39 Million INR | -25.6% |
| 2022 | 561.84 Million INR | 4.63% |
| 2021 | 536.99 Million INR | 44.21% |
| 2020 | 372.37 Million INR | 23.74% |
| 2019 | 300.94 Million INR | -8.91% |
| 2018 | 330.38 Million INR | 1.96% |
| 2017 | 324.03 Million INR | -4.04% |
| 2016 | 337.67 Million INR | 0.04% |
| 2015 | 337.52 Million INR | -12.24% |
| 2014 | 384.6 Million INR | 5.64% |
| 2013 | 364.05 Million INR | 33.57% |
| 2012 | 272.55 Million INR | 122.42% |
| 2011 | 122.54 Million INR | -79.4% |
| 2010 | 594.87 Million INR | 3155.07% |
| 2009 | 18.27 Million INR | 182.48% |
| 2008 | 6.46 Million INR | -11.23% |
| 2007 | 7.28 Million INR | 134.03% |
| 2006 | -21.41 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 126.38 Million INR | -8.14% |
| 2023 Q4 | 137.58 Million INR | -30.16% |
| 2023 Q3 | 196.99 Million INR | 2.56% |
| 2023 Q2 | 192.07 Million INR | 1.48% |
| 2023 Q1 | 189.26 Million INR | 151.21% |
| 2023 FY | 418.01 Million INR | -25.6% |
| 2022 Q1 | 156.84 Million INR | 51.63% |
| 2022 FY | 561.84 Million INR | 4.63% |
| 2022 Q4 | 75.34 Million INR | -57.93% |
| 2022 Q3 | 179.06 Million INR | 18.96% |
| 2022 Q2 | 150.52 Million INR | -4.03% |
| 2021 Q4 | 103.44 Million INR | -32.3% |
| 2021 Q2 | 158.67 Million INR | 29.98% |
| 2021 Q3 | 152.79 Million INR | -3.71% |
| 2021 FY | 536.99 Million INR | 44.21% |
| 2021 Q1 | 122.07 Million INR | 92.4% |
| 2020 Q3 | 134.27 Million INR | 35.55% |
| 2020 Q4 | 63.44 Million INR | -52.75% |
| 2020 FY | 372.37 Million INR | 23.74% |
| 2020 Q1 | 76.46 Million INR | 278.38% |
| 2020 Q2 | 99.06 Million INR | 29.56% |
| 2019 Q4 | -42.86 Million INR | -140.31% |
| 2019 Q1 | 112.25 Million INR | 2322.95% |
| 2019 Q2 | 126.09 Million INR | 12.32% |
| 2019 Q3 | 106.32 Million INR | -15.68% |
| 2019 FY | 300.94 Million INR | -8.91% |
| 2018 Q1 | 92.91 Million INR | -8.81% |
| 2018 FY | 330.38 Million INR | 1.96% |
| 2018 Q4 | 4.63 Million INR | -95.89% |
| 2018 Q3 | 112.8 Million INR | -6.02% |
| 2018 Q2 | 120.03 Million INR | 29.18% |
| 2017 Q2 | 109.66 Million INR | 11.5% |
| 2017 FY | 324.03 Million INR | -4.04% |
| 2017 Q4 | 101.89 Million INR | -5.19% |
| 2017 Q3 | 107.47 Million INR | -2.0% |
| 2017 Q1 | 98.35 Million INR | -22.47% |
| 2016 Q1 | 97.27 Million INR | 35.1% |
| 2016 FY | 337.67 Million INR | 0.04% |
| 2016 Q4 | 126.86 Million INR | 0.0% |
| 2015 Q3 | 78.43 Million INR | -17.03% |
| 2015 Q1 | 96.53 Million INR | -23.85% |
| 2015 Q2 | 94.53 Million INR | -2.07% |
| 2015 FY | 337.52 Million INR | -12.24% |
| 2015 Q4 | 72 Million INR | -8.21% |
| 2014 Q3 | 102.5 Million INR | -5.04% |
| 2014 Q1 | 89.51 Million INR | 43.13% |
| 2014 Q2 | 107.94 Million INR | 20.58% |
| 2014 FY | 384.6 Million INR | 5.64% |
| 2014 Q4 | 126.76 Million INR | 23.66% |
| 2013 Q2 | 97.48 Million INR | 18.09% |
| 2013 Q4 | 62.54 Million INR | -29.42% |
| 2013 FY | 364.05 Million INR | 33.57% |
| 2013 Q1 | 82.55 Million INR | -62.03% |
| 2013 Q3 | 88.6 Million INR | -9.11% |
| 2012 Q4 | 217.38 Million INR | 232.7% |
| 2012 Q2 | 76.38 Million INR | 44.42% |
| 2012 Q3 | 65.34 Million INR | -14.46% |
| 2012 Q1 | 52.88 Million INR | 0.0% |
| 2012 FY | 272.55 Million INR | 122.42% |
| 2011 FY | 122.54 Million INR | -79.4% |
| 2010 FY | 594.87 Million INR | 3155.07% |
| 2009 FY | 18.27 Million INR | 182.48% |
| 2008 FY | 6.46 Million INR | -11.23% |
| 2007 FY | 7.28 Million INR | 134.03% |
| 2006 FY | -21.41 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Ajanta Pharma Limited | 30.46 Billion INR | 96.906% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | 14.248% |
| Sigachi Industries Limited | 579.88 Million INR | -62.514% |
| Bal Pharma Limited | 389.89 Million INR | -141.709% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | 55.635% |
| Medico Remedies Limited | 161.84 Million INR | -482.289% |
| Lasa Supergenerics Limited | 291.17 Million INR | -223.655% |
| Venus Remedies Limited | 1.91 Billion INR | 50.822% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 69.371% |
| Alpa Laboratories Limited | 156.14 Million INR | -503.533% |
| Nectar Lifesciences Limited | 625.55 Million INR | -50.651% |
| Shilpa Medicare Limited | 2.18 Billion INR | 56.782% |
| Aarti Drugs Limited | 1.16 Billion INR | 19.279% |
| Lupin Limited | 95.67 Billion INR | 99.015% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 97.598% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 97.817% |
| Windlas Biotech Limited | 1 Billion INR | 6.37% |
| Suven Life Sciences Limited | 109.75 Million INR | -758.678% |
| Eris Lifesciences Limited | 4.94 Billion INR | 80.934% |
| Valiant Laboratories Limited | 36.28 Million INR | -2496.927% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 88.804% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | 79.422% |
| Ipca Laboratories Limited | 13.91 Billion INR | 93.227% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | 33.597% |
| Achyut Healthcare Limited | 1.6 Million INR | -58470.479% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.389% |
| Bajaj HealthCare Limited | 985.34 Million INR | 4.358% |
| RPG Life Sciences Limited | 1.63 Billion INR | 42.379% |
| Mankind Pharma Limited | 23.15 Billion INR | 95.93% |
| Laurus Labs Limited | 3.01 Billion INR | 68.699% |
| Piramal Pharma Limited | 19.91 Billion INR | 95.268% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 95.601% |
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 94.062% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 98.605% |
| Unichem Laboratories Limited | 6.72 Billion INR | 85.988% |
| Sequent Scientific Limited | 2.9 Billion INR | 67.524% |
| Novartis India Limited | 470.1 Million INR | -100.468% |
| Wanbury Limited | 1.16 Billion INR | 18.824% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | 32.82% |
| Wockhardt Limited | 6.4 Billion INR | 85.275% |
| Themis Medicare Limited | 782.85 Million INR | -20.38% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -21.85% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 93.48% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 91.904% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.017% |
| Divi's Laboratories Limited | 14.17 Billion INR | 93.349% |
| NATCO Pharma Limited | 10.05 Billion INR | 90.63% |
| Gufic Biosciences Limited | 1.07 Billion INR | 12.555% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | 14.234% |
| Ind-Swift Limited | 946.56 Million INR | 0.44% |
| Procter & Gamble Health Limited | 2.99 Billion INR | 68.538% |
| FDC Limited | 5.34 Billion INR | 82.38% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -1941.769% |
| Granules India Limited | 7.18 Billion INR | 86.879% |
| Medicamen Biotech Limited | 335.16 Million INR | -181.173% |
| Alkem Laboratories Limited | 32.83 Billion INR | 97.13% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | 63.759% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -5713.797% |
| Brooks Laboratories Limited | 51.18 Million INR | -1741.342% |
| Megasoft Limited | 49.52 Million INR | -1802.76% |
| ZIM Laboratories Limited | 1.01 Billion INR | 6.975% |
| Strides Pharma Science Limited | 9.16 Billion INR | 89.714% |
| Neuland Laboratories Limited | 2.92 Billion INR | 67.833% |
| Morepen Laboratories Limited | 1.98 Billion INR | 52.583% |
| Hikal Limited | 2.48 Billion INR | 62.097% |
| Indoco Remedies Limited | 4.74 Billion INR | 80.155% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 69.347% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -128.501% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -39.378% |
| Hester Biosciences Limited | 908.84 Million INR | -3.693% |